-
-
-
-
-
-
-
Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia
-
-
-
-
-
-
-
Aptinyx (APTX) Reports Phase 2b Study of NYX-2925 Did Not Achieve Statistical Significance
-
-
-
-
-
-
-
Aptinyx Highlights Key Goals and Anticipated Development Milestones for 2022
-
-
-
-
-
-
-
Aptinyx (APTX) Misses Q2 EPS by 4c
-
-
-
-
-
-
-
Aptinyx (APTX) Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy Bodies
-
-
-
-
-
-
-
Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer
-
-
-
-
-
-
-
Pre-Open Stock Movers 10/20: (APTX) (RWLK) (LOGI) Higher; (HXL) (CVNA) (IBM) Lower (more...)
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

